VivoSeq
Infectious Disease

Hepatitis C

248

Pipeline Programs↗

7

Active Trials↗

60

Companies Involved↗

Hepatitis C is a highly competitive landscape with 248 programs across 60 companies. The most active players are Enanta Pharmaceuticals, Inc, Presidio Pharmaceuticals, Inc., Akros Pharma Inc.. 40 therapies are approved with 44 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

83/100

Pipeline Velocity

11/100

Mech. Concentration

7/100

Completion Rate

85/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Enanta Pharmaceuticals, Inc

2 programs

Phase 1P

Presidio Pharmaceuticals, Inc.

2 programs

Phase 1A

Akros Pharma Inc.

2 programs

Phase 1I

Idera Pharmaceuticals, Inc.

1 program

Phase 1M

MassBiologics

1 program

Phase 1G

GeneCure Biotechnologies

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical23

Aldesleukin

Iovance Biotherapeutics, Inc.

Ribavirin

Conrado Roberto Hoffmann Filho

Buprenorphine/naloxone

Astellas

Paroxetine

Sebela Pharmaceuticals Development LLC

Direct Acting Antivirals

Post Graduate Institute of Medical Education and Research, Chandigarh

Phase 151

Efavirenz

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

EDP239

Enanta Pharmaceuticals, Inc

Ritonavir

AbbVie

IMO-2125

Idera Pharmaceuticals, Inc.

MB-110

Microbio Co Ltd

Phase 290

BMS-986094

Bristol-Myers Squibb

VX-936

Vertex Pharmaceuticals

Rituximab

Roche

Prednisone

Roxane Laboratories

Infliximab

Organon and Co

Phase 344

Ezetimibe

Organon and Co

Escitalopram

AbbVie

Ombitasvir/paritaprevir/ritonavir

AbbVie

Pegifn/rbv

Boehringer Ingelheim

Alisporivir

Debiopharm International SA

Approved40

Maraviroc

GSK

Pioglitazone

Takeda

Everolimus

Novartis

Cyclosporine

Novartis

Zidovudine

Bp Consulting, Inc

Analysis

Modality Breakdown

98%

Small molecule

281 of 286 classified programs — the dominant modality here.

2%ALL OTHERSMonoclonal antibody31%Protein / enzyme1<1%Vaccine1<1%

Small molecule leads; the ring shows all 286 classified programs, each share of the total. Modality classified for 100% of 307 pipeline programs.

Analysis

Trial Status

411

clinical trials

Completed312 · 76%
Terminated39 · 9%
Unknown status35 · 9%
Withdrawn16 · 4%
Recruiting3 · 1%
Not yet recruiting2 · 0%
Other4 · 1%

Clinical Trials

Trial Activity

411 trials

The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry
Recruiting·TThe Task Force for Global Health·N/A·NCT05368974·100 enrolled
Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania
Recruiting·—·Phase 1·NCT06159504·3,040 enrolled
Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT07040319·30 enrolled
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
Active, not recruiting·MMayo Clinic·Phase 4·NCT04508907·200 enrolled
Hepatitis C Treatment in Idaho County Jails
Not yet recruiting·EEastern Idaho Public Health·N/A·NCT06533319·100 enrolled
Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy
Not yet recruiting·AANRS, Emerging Infectious Diseases·Phase 4·NCT07098481·576 enrolled
Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan
Enrolling by invitation·QQueen Mary University of London·N/A·NCT05248919·318 enrolled
Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED)
Completed·SSchering-Plough·N/A·NCT00705263·113 enrolled
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 3·NCT01330316·119 enrolled
Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects
Completed·EEnanta Pharmaceuticals, Inc·Phase 1·NCT01856426·28 enrolled
Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine
Completed·VValneva Austria GmbH·Phase 2·NCT00602784·66 enrolled
Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients
Completed·IIdera Pharmaceuticals, Inc.·Phase 1·NCT00990938·63 enrolled
Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected Subjects
Completed·AAkros Pharma Inc.·Phase 1·NCT01473056·29 enrolled
An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C
Completed·Pfizer logoPfizer·Phase 4·NCT00141284·12 enrolled
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
Completed·AbbVie logoAbbVie·Phase 3·NCT02939989·33 enrolled
Page 1 of 28

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)